文献速递神经肿瘤

硼中子俘获治疗复发脑膜瘤的可行性研究:剂量学与临床相关性

Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates.
PubMed 文献 · J Neurooncol · 2025-07-31

该回顾性研究分析了13例在清华开池反应堆接受挽救性BNCT的复发脑膜瘤患者,采用¹⁸F-BPA或¹⁸F-Fluciclovine PET评估肿瘤摄取,RANO标准评价疗效。5例(38%)响应,响应者肿瘤平均剂量显著更高(45.10 vs. 25.85 GyE,p=0.003),非颅底肿瘤剂量更高且响应趋势更好,未观察到严重不良事件。

要点

  • 复发脑膜瘤挽救性BNCT可行且耐受良好,38%患者响应。
  • 响应者肿瘤平均剂量显著更高(45.10 vs. 25.85 GyE,p=0.003)。
  • 非颅底肿瘤剂量更高且响应趋势更好,TNR和肿瘤大小不预测响应。

核心结论

  • 挽救性BNCT是复发脑膜瘤可行且耐受良好的治疗,剂量分布和肿瘤位置显著影响治疗响应。

研究设计与样本

  • 回顾性分析2020年8月至2024年5月在清华开池反应堆接受挽救性BNCT的13例复发脑膜瘤患者。
  • 采用¹⁸F-BPA或¹⁸F-Fluciclovine PET评估肿瘤摄取,RANO标准评价治疗响应。

主要发现

  • 13例患者中5例(38%)对BNCT响应,包括1例WHO 3级、6例2级和6例1级。
  • 响应者肿瘤平均剂量显著高于非响应者(45.10 vs. 25.85 GyE,p=0.003)。
  • 非颅底肿瘤接受更高剂量且显示更好响应趋势,TNR和肿瘤大小不预测响应。
  • 未观察到严重不良事件。

临床怎么用

  • 对复发脑膜瘤可考虑挽救性BNCT,尤其非颅底病变,并关注肿瘤剂量分布。

局限性

  • 回顾性研究,样本量小(13例),需进一步研究优化影像和计划策略,特别是颅底病变和Fluciclovine PET情境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Boron neutron capture therapy (BNCT) is a targeted radiotherapy modality that has shown promise in the treatment of recurrent gliomas and head and neck cancers. Although meningiomas are generally slow-growing, recent studies have demonstrated favorable uptake of boron-containing compounds, particularly boronophenylalanine (BPA), suggesting a potential role for BNCT in recurrent meningioma. METHODS: We retrospectively analyzed 13 patients with recurrent meningiomas treated with salvage BNCT at the Tsing Hua Open-Pool Reactor between August 2020 and May 2024. Tumor uptake was assessed using either ¹⁸F-BPA or ¹⁸F-Fluciclovine PET. Treatment response was evaluated using RANO criteria, and outcomes were analyzed in relation to dosimetric and clinical factors. RESULTS: Of the 13 patients (1 WHO grade 3, 6 grade 2, and 6 grade 1), 5 (38%) responded to BNCT. Responders had significantly higher tumor mean dose (45.10 vs. 25.85 GyE, p = 0.003). Tumor location influenced dosimetry; non-skull base tumors received higher doses and showed a trend toward better response. TNR and tumor size were not predictive of response. No severe adverse events were observed. CONCLUSIONS: Salvage BNCT is a feasible and well-tolerated treatment for recurrent meningioma, with dose distribution and tumor location significantly influencing treatment response. Further studies are warranted to refine imaging and planning strategies, particularly for skull base lesions and in the context of Fluciclovine PET.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lan TL, Lin CF, Lee YY, et al. Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates. J Neurooncol. 2025. PMID: 40745077. doi:10.1007/s11060-025-05184-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。